Light chain (AL) Amyloidosis/Primary

Background: Treatment options for patients (pts) with relapsed/refractory (RR) AL amyloidosis are limited. Daratumumab (dara) has been approved as monotherapy (DMT…

Much like multiple myeloma, the treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies, says Michael…

Systemic amyloidosis is caused by misfolding and extracellular deposition of circulating proteins as amyloid fibrils, resulting in the dysfunction of vital organs.…

The disease causing agent in systemic AL amyloidosis is a monoclonal immunoglobulin free light chain, or fragments thereof, circulating in the blood. It is not…

The amyloidoses are a group of protein-folding disorders in which >=1 organ is infiltrated by proteinaceous deposits known as amyloid. The deposits are derived…

AL amyloidosis is treated with the same set of chemotherapy drugs that are used to treat multiple myeloma. However, it is important for patients with AL amyloidosis…

What is AL amyloidosis? The term 'amyloidosis' is a general term used for a group of conditions where an abnormal protein, called amyloid, accumulates in the…

AL Amyloidosis and Agent Orange Veterans who develop AL amyloidosis and were exposed to Agent Orange or other herbicides during military service do not have to…

Dysphagia is an uncommon presentation of systemic immunoglobulin light-chain (AL) amyloidosis with multiple myeloma (MM). Gastrointestinal (GI) involvement usually…

An elderly Caucasian man presented with a 10-month history of proximal myopathy and dysphagia. His serum creatine kinase (CK) was elevated at 877 U/L (normal 40-320…